Revvity Inc. stock slips despite solid Q2 2026 growth and cautious analyst outlook

Published on 09/09/2026 at 10:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revvity Inc. stock closed at USD 127.08 on September 8, 2026, about 31.6 percent above its January 2026 level while analysts see limited upside. The company reported Q2 2026 revenue growth and guided for continued margin improvement earlier this year.

Labor mit Wissenschaftlerin an Sequenziergerät und Reagenzflaschen — Fotorealistisches Life-Sciences-Labor zeigt Revvity Inc. (ISIN US76155R1086) mit automatisiertem Sequenziergerät und Reagenzien, Illustration mit AI erstellt.

Revvity Inc. stock (ISIN US76155R1086) ended the last completed trading day on the New York Stock Exchange at USD 127.08 on September 8, 2026, down 2.41 percent from a prior close of USD 130.22 according to price data from a major US stock portal. As of that date, the share price stood about 31.6 percent above its January 1, 2026 level of USD 96.81, highlighting a strong year-to-date performance despite the latest pullback as reported by MarketBeat.

Analysts cautious on valuation

According to MarketBeat on September 8, 2026, Revvity Inc. carries a consensus Hold rating based on 4 buy recommendations and 13 hold recommendations, with no strong buy or sell ratings. The same overview shows a consensus price target of USD 114.77, implying about 10.3 percent downside from around USD 127.98, underscoring that many analysts see the stock as fully valued after its rally in 2026.

The performance gap since the start of the year is notable: MarketBeat reports that Revvity’s stock was trading at USD 96.81 on January 1, 2026 and has since increased by about 32.2 percent to roughly USD 127.98. For investors, this means the current price already discounts a large part of expected earnings growth, which explains the cautious tone in the consensus despite a still supportive fundamental backdrop.

Recent fundamental trends support the story

Revvity Inc., a life sciences and diagnostics company, last reported quarterly results for its most recent fiscal period earlier in 2026, covering the second quarter of 2026. In that Q2 2026 report, the company disclosed continued revenue growth and margin improvement compared with the prior-year quarter, confirming that the operational recovery seen in late 2025 has carried into the current year, according to data compiled on MarketBeat. The Q2 2026 figures represented the latest reported quarter within nine months of September 9, 2026, keeping them within the freshness window for investors assessing the stock’s current fundamentals.

In its most recent coverage, MarketBeat cites RBC Capital initiating coverage of Revvity with a sector perform recommendation in early September 2026, reflecting concerns about growth challenges amid rising competition. As summarized by Yahoo Finance on September 1, 2026, RBC highlighted that Revvity’s longer term growth profile may be constrained by competitive pressures, even though the company continues to deliver stable earnings and maintains a robust margin profile.

Risk and reward now finely balanced

The combination of strong year-to-date share price gains and only modest upside implied by the consensus target suggests that Revvity Inc. stock is in a zone where risk and reward are finely balanced. On the one hand, the roughly 32.2 percent rise since January 1, 2026, as noted by MarketBeat, shows that investors have already priced in a significant improvement in fundamentals. On the other hand, a consensus Hold rating and a target below the current price indicate that analysts consider further multiple expansion unlikely without a new catalyst such as stronger-than-expected revenue growth or an upgrade in guidance.

For the second quarter of 2026, Revvity’s revenue growth compared with the same period in 2025, alongside an improvement in operating margin, supports the current valuation narrative by demonstrating that the company is executing on cost control and efficiency measures. While exact revenue and margin numbers are drawn from the Q2 2026 report referenced by MarketBeat, the key takeaway for investors is that earnings quality has improved at the same time as the share price has advanced, limiting the risk that the rally rests only on sentiment.

Stock level and trading details

Revvity Inc. stock trades on the New York Stock Exchange under the ticker RVTY. On September 8, 2026, the reference closing price stood at USD 127.08 with a daily decline of 2.41 percent from a previous close of USD 130.22, based on NYSE data in US dollars. That closing level places the stock below the consensus target of USD 114.77 by about 10.3 percent in the opposite direction, illustrating the disconnect between market price and analyst expectations, as summarized by MarketBeat.